Corpus Intelligence IC Memo — GLENWOOD REGIONAL MEDICAL CENTER 2026-04-26 04:05 UTC
IC Memo — GLENWOOD REGIONAL MEDICAL CENTER
Investment Committee Memorandum | LA | 218 beds | Grade C | EBITDA uplift $13.6M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

GLENWOOD REGIONAL MEDICAL CENTER

CCN 190160 | OUACHITA PARISH, LA | 218 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

GLENWOOD REGIONAL MEDICAL CENTER is a 218-bed suburban community hospital in OUACHITA PARISH, LA with $184.5M in net patient revenue and a -5.9% operating margin. The hospital serves a payer mix of 35.7% Medicare, 1.8% Medicaid, and 62.5% commercial.

Thesis: Undervalued. Our ML models identify $13.6M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -5.9% to 1.4% (+736bps).

Net Revenue HCRIS$184.5M
Current EBITDA COMPUTED$-11.0M
Operating Margin COMPUTED-5.9%
Occupancy HCRIS43.2%
Revenue / Bed COMPUTED$846K
Net-to-Gross HCRIS17.7%
Distress Probability ML49.0%

2. Market Context & Competitive Position

212
LA Hospitals
-3.5%
State Median Margin
38
Comparable Hospitals

LA has 212 Medicare-certified hospitals with a median operating margin of -3.5%. The target's margin of -5.9% places it below the state median. Among 38 size-comparable peers (109-436 beds), the median margin is -8.3%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (109-436), prioritizing same-state peers. 38 hospitals in the comp set.

HospitalStateBedsRevenueMargin
GLENWOOD REGIONAL MEDICAL CENT (Target)LA218$184.5M-5.9%
UNIVERSITY MEDICAL CTR. AT NEWLA310$671.3M-22.4%
CHILDRENS HOSPITALLA189$523.4M6.7%
OUR LADY OF LOURDES RMCLA363$509.6M8.9%
TULANE UNIVERSITY HOSPITAL & CLA431$490.2M-14.1%
LAFAYETTE GENERAL MEDICAL CENTLA390$480.2M-16.4%
BATON ROUGE GENERALLA251$445.5M-6.7%
ST. TAMMANY PARISH HOSPITALLA213$434.6M4.5%
OCHSNER LSU HEALTH SHREVEPORTLA273$395.6M-50.0%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $13.6M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$3.9M+210bp18mo
Cost to Collect4.5%2.5%$3.7M+200bp12mo
Denial Rate Reduction12.0%6.5%$3.7M+198bp12mo
A/R Days Reduction5200.0%3800.0%$2.2M+122bp9mo
Clean Claim Rate88.0%96.0%$118K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$3.9M
Cost to Collect
$3.7M
Denial Rate Reduction
$3.7M
A/R Days Reduction
$2.2M
Clean Claim Rate
$118K
Total EBITDA Uplift$13.6M
Current EBITDA$-11.0M
+ RCM Uplift+$13.6M
Pro Forma EBITDA$2.6M
Current Margin-5.9%
Pro Forma Margin1.4%
WC Released (1x)$7.1M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-16.9M$63.6M0.00x-100.0%
Base (11x exit)10.0x11.0x$-16.9M$64.5M0.00x-100.0%
Bull Case9.0x11.0x$-15.2M$103.8M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-15.2M$108.8M0.00x-100.0%
Bear Case11.0x10.0x$-18.5M$1.1M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-18.5M$-4.8M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 38 hospitals with 109-436 beds
  • Same-state prioritization (n=39)
  • Comp margins: P25=-17.7% / P50=-8.3% / P75=-1.1%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.